Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis

BACKGROUND: FOLFIRINOX (fluorouracil, folinic acid, irinotecan plus oxaliplatin) is an effective standard first-line treatment option for advanced pancreatic ductal adenocarcinoma (PDAC). There is no clear consensus on the second-line treatment following progression on FOLFIRINOX. In this multicente...

詳細記述

保存先:
書誌詳細
出版年:Ther Adv Med Oncol
主要な著者: Chae, Heejung, Jeong, Hyehyun, Cheon, Jaekyung, Chon, Hong Jae, Ryu, Hyewon, Kim, Il-Hwan, Kang, Myoung Joo, Jeong, Jae Ho, Ryoo, Baek-Yeol, Kim, Kyu-pyo, Yoo, Changhoon
フォーマット: Artigo
言語:Inglês
出版事項: SAGE Publications 2020
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7257856/
https://ncbi.nlm.nih.gov/pubmed/32523632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920923424
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料